ALLERGAN'S ACULAR RECEIVES ADDITIONAL INDICATION; Postoperative Inflammation Following Cataract Extraction.IRVINE, Calif.--(HealthWire)--Jan. 6, 1997--Allergan Inc. (NYSE NYSE See: New York Stock Exchange : AGN AGN Again (Amateur Radio) AGN Active Galactic Nucleus AGN Acute Glomerulonephritis AGN Accountants Global Network AGN Air Gabon (ICAO code) ) today announced that it has received clearance from the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) to market ACULAR (ketorolac tromethamine ketorolac tromethamine Acular, Acular LS Pharmacologic class: Nonsteroidal anti-inflammatory drug (NSAID) Therapeutic class: Analgesic, antipyretic, anti-inflammatory Pregnancy risk category C ophthalmic solution ophthalmic solution n. A sterile solution that is free from foreign particles and is compounded and dispensed for eyedrops. ) 0.5% in the United States for the treatment of postoperative inflammation in patients who have undergone cataract extraction. An estimated 1.6 million cataract surgeries are performed in the United States each year. "ACULAR has been one of the top growth products in our ophthalmic pharmaceutical business," said Allergan Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. William C. Shepherd. "This new indication should strengthen its market position in the topical NSAID NSAID: see nonsteroidal anti-inflammatory drug. category." Last month Allergan filed the application for U.S. marketing approval for ocular pain following incisional refractive surgery Refractive surgery A surgical procedure that corrects visual defects. Mentioned in: Photorefractive Keratectomy and Laser-Assisted In-Situ Keratomileusis refractive surgery . In November of 1992, ACULAR received FDA marketing clearance for the relief of ocular itch associated with seasonal allergic conjunctivitis. ACULAR was the first non- steroidal anti-inflammatory drug (NSAID) to receive marketing clearance for this indication. Any of the above statements that refer to the Company's estimated or anticipated future results are forward-looking and reflect the Company's current analysis of existing trends and information. Actual results may differ from current expectations based on a number of factors affecting Allergan's businesses including competitive conditions and changing market conditions, the timing and uncertainty of results of both research and regulatory processes and performance, including patient acceptance of new products, the impact of the Company's previously announced strategic restructuring and the results of geographic expansion efforts. These forward-looking statements represent the Company's judgment only as of the date of this press release. Actual results could differ materially from those projected in this release. As a result, the reader is cautioned not to rely on these forward-looking statements. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Allergan, Inc., headquartered in Irvine, Calif., is a technology-driven, global health care company, focused on specialty pharmaceutical products for specific disease areas that deliver value to customers, satisfy unmet medical needs and improve patients' lives. CONTACT: Allergan, Irvine Jeff D'Eliscu 714/246-4636 (office) 714/675-9475 (home) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion